GlobeNewswire

Maricopa Region 911 Calls on Corvil to Bolster Emergency Response Services

Dela

Insight from Corvil Analytics helps assure public safety through optimal caller interaction and servicing

NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Maricopa Region 911, servicing the Phoenix metro area, which includes the fifth largest city in the US, has enlisted Corvil to provide real-time visibility and analytics to assure the quality, performance, and availability of critical emergency communications services across its existing Emergency Services IP network (ESInet), part of Maricopa Region 911's Next Generation 9-1-1 (NG911) deployment.

Delivering nearly 2.5 million wireless calls each year for police, fire, and medical assistance to 27 Public Service Answering Point (PSAP) locations across the region, Maricopa Region 911 provides potentially lifesaving technologies including 911 call delivery and advanced mapping to provide location intelligence using internet-based imagery to hundreds of 911 call taking positions.

Maricopa Region 911 has been moving towards VoIP call delivery, with continuity of operations as a prerequisite. This replaces analog emergency call services with digital communications services and allows for additional NG911 applications, provided over a converged network with increased service assurance requirements.  Maricopa Region 911 deployed Corvil to gain the operational intelligence required to support consistent end-to-end quality of service, with Corvil now providing visibility into the more than 70 percent of calls that have already migrated to VoIP.

"Corvil is providing analytics and actionable insight into our network traffic that previously wasn't available," said Dave Dansevicus, 911 Integrated Systems Administrator.  "Right out of the box, Corvil identified a vendor configuration issue, enabling us to proactively improve performance.  Now, these insights allow one person to get data needed to troubleshoot in minutes, where previously it would require multiple entities and could take over a day.  It seems we find a new use case enabled by Corvil every week." 

Corvil's real-time network analytics empower Maricopa Region 911 with the insight required to meet their "zero tolerance" objective for poor caller experience such as jittery, choppy or garbled calls.  Offering live and retrospective quality metrics such as mean opinion scores, jitter, and packet loss by caller number, time of day, call volumes and other call record details, Corvil delivers advanced, data-driven analytics to proactively identify service degradation, optimize performance, and respond to issues.

"We are proud and delighted to be working with Maricopa Region 911 to support such an important public safety service,"  said Dan Kennedy, Corvil VP and General Manager, Americas.  "Working together to deliver a quality service outcome, we have established a strong partnership that we believe will continue to deliver value well into the future."

Corvil is also delivering operational efficiencies. Through seamless integration with the existing IT Operations Analytics (ITOA) ecosystem, Corvil allows Maricopa Region 911 to maintain the single user interface with which all technical team members are already familiar, thereby extending Corvil intelligence to the broader team, minimizing the learning curve for expanded adoption, and shortening troubleshooting times.  Using the Corvil VoIP Performance App for a leading machine data platform, for example, Maricopa Region 911 operational team members use single-click workflows to contextually navigate to further explore more granular details and analysis within Corvil Analytics or export Corvil data to enable offline investigation or sharing with others.

"By supplying near-real-time access to accurate data that can be shared with our partners - using the tools with which we are already familiar - Corvil has already allowed us to eliminate process bottlenecks and shorten troubleshooting times.  This information also validates our data network is performing as we expect - all to ensure the highest level of 911 service to our community,"  said Dansevicus.

" Our partnership with Maricopa Region 911 exemplifies the important role operational analytics play in supporting the quality delivery, assessment, and improvement of critical services ," said David Murray, Corvil Chief Marketing and Business Development Officer.  " It also highlights the value and importance of our seamless integration with existing customer ecosystems to accelerate improved responsiveness, mean time to repair, staff productivity and customer return on investment."            

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Media Contact
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum